John P. Schmid bought $96k of BLSM
director at BlossomHill Therapeutics, Inc.. 6,000 shares at an average of $16.00, traded Aug 10, 2026, filed Aug 10, 2026.
Score components
- +15RoleDirector
- +10Trade size$96k at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- 0Price contextNo price history yet
- +15Cluster6 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001478916-26-000015, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 10, 2026 | POpen-market purchase Common Stock | +6,000 | $16.00 | $96k | 6,000 | Aug 10, 2026 |
Related signals
Other insiders at BlossomHill Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 56Moderate | BlossomHill Therapeutics, Inc. | Orbimed Advisors LLC director | $10M 625,000 shares | +30% | |
| 61Notable | BlossomHill Therapeutics, Inc. | Carl L Gordon director | $10M 625,000 shares | +30% | |
| 58Moderate | BlossomHill Therapeutics, Inc. | Bihua Chen director, owner | $5.0M 312,500 shares | +9% | |
| 45Moderate | BlossomHill Therapeutics, Inc. | Jason A Keyes Chief Financial Officer | $11k 700 shares | - | |
| 38Weak | BlossomHill Therapeutics, Inc. | Vincent Paul Liptak General Counsel | $75k 4,700 shares | +4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.